RNA
Atrium Therapeutics, Inc.
Healthcare — Biotechnology
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Strong Buy
1.0 / 5
3 analysts
$8.14
$-0.14 (-1.69%)
Target:
$25.00
(207.1%)
Price History
52-Week Range
Sign in to add RNA to a watchlist or set price alerts.
Fundamentals
| Market Cap | $227.51M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.27 |
| EPS (TTM) | $-5.02 |
| Dividend Yield | - |
| Profit Margin | -159.99% |
| Revenue Growth | 1148.30% |
| ROE | - |
| Debt/Equity | 1.15 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $25.00 |
| Analysts | 3 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 74.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.77 |
| 52-Week Low | $11.40 |
| 50-Day Avg | $12.88 |
| 200-Day Avg | $13.33 |
| Avg Volume | 299.3K |
| Volume | 143.5K |
Performance Analysis
NEUTRALRNA presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($11.40), which could present a value opportunity.
-
RSI at 74.3 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 1148.3% year-over-year.
-
Operating at a loss with -160.0% margin.
+
Wall Street consensus is "Strong Buy" from 3 analysts.
+
Average analyst target of $25.00 implies 207.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report